Prolor Biotech reported positive preclinical results from an animal study of its long-acting obesity/Type II diabetes drug candidate MOD-6030. During the trial, the drug was administered to diet-induced obese mice once weekly over a 30-day period. According to Prolor, the results demonstrated efficacy in reducing weight, lowering blood glucose levels, increasing insulin sensitivity and reducing cholesterol levels as compared to a group that received placebo.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments